Cytokine Kinetics in Febrile Neutropenic Children: Insights on the Usefulness as Sepsis Biomarkers, Influence of Filgrastim, and Behavior of the IL-23/IL-17 Pathway

被引:17
作者
de Araujo, Orlei Ribeiro [1 ]
Salomao, Reinaldo [2 ]
Colo Brunialti, Milena Karina [2 ]
Bourguignon da Silva, Dafne Cardoso [1 ]
Senerchia, Andreza Almeida [1 ]
de Moraes Costa Carlesse, Fabianne Altruda [1 ]
Petrilli, Antonio Sergio [1 ]
机构
[1] Sao Paulo Fed Univ UNIFESP, Grp Apoio Adolescente & Crianca Canc GRAACC, IOP, Rua Pedro de Toledo 572, BR-04039001 Sao Paulo, SP, Brazil
[2] Sao Paulo Fed Univ UNIFESP, Div Infect Dis, Dept Med, Escola Paulista Med, Rua Pedro de Toledo 669,10th Floor, BR-04039001 Sao Paulo, SP, Brazil
基金
巴西圣保罗研究基金会;
关键词
TUMOR-NECROSIS-FACTOR; IL-23; FEVER; DIFFERENTIATION; ENDOTOXIN;
D O I
10.1155/2017/8291316
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Background. The study aimed to describe the kinetics of various cytokines from day 1 to day 14 of the onset of fever in neutropenic children and to evaluate their performances as discriminators of sepsis in the first 24 hours of fever, the possible influence of filgrastim, and the functioning of the IL-23/IL-17 axis. Methods. IL-1 beta, TNF-alpha, IL-10, IL-12/23p40, IL-21, IL-6, IL-8, IL-17, G-CSF, and GM-CSF were measured in plasma on days 1, 2, 3, 5, and 14 from the onset of fever in 35 patients. Results. Thirteen patients (37.1%) developed sepsis. In mixed models, IL-6, IL-8, IL-10, and G-CSF showed higher estimated means in septic patients (P < 0 005), and IL-12/23p40 and IL-17 in nonseptic patients (P < 0 05). On day 1, IL-6, IL-8, and IL-10 appeared upregulated in patients who received filgrastim. Only IL-6, IL-8, IL-10, and procalcitonin were useful as discriminators of sepsis. Associating the markers with each other or to a risk assessment model improved performance. Conclusions. Cytokines kinetics showed proinflammatory and anti-inflammatory responses similar to what is described in nonneutropenic patients. IL-8, IL-6, IL-10, and procalcitonin are useful as early biomarkers of sepsis. Filgrastim upregulates expression of these markers, and we observed deficiency in the IL-23-IL-17 axis accompanying sepsis.
引用
收藏
页数:10
相关论文
共 34 条
[1]   Endotoxin tolerance: new mechanisms, molecules and clinical significance [J].
Biswas, Subhra K. ;
Lopez-Collazo, Eduardo .
TRENDS IN IMMUNOLOGY, 2009, 30 (10) :475-487
[2]   Fever and neutropenia: the early years [J].
Bodey, Gerald P. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 63 :I3-I13
[3]   Therapeutic potential of targeting IL-17 and IL-23 in sepsis [J].
Bosmann, Markus ;
Ward, Peter A. .
CLINICAL AND TRANSLATIONAL MEDICINE, 2012, 1
[4]   CIRCULATING INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR IN SEPTIC SHOCK AND EXPERIMENTAL ENDOTOXIN FEVER [J].
CANNON, JG ;
TOMPKINS, RG ;
GELFAND, JA ;
MICHIE, HR ;
STANFORD, GG ;
VANDERMEER, JWM ;
ENDRES, S ;
LONNEMANN, G ;
CORSETTI, J ;
CHERNOW, B ;
WILMORE, DW ;
WOLFF, SM ;
BURKE, JF ;
DINARELLO, CA .
JOURNAL OF INFECTIOUS DISEASES, 1990, 161 (01) :79-84
[5]   Increased Percentages of T Helper Cells Producing IL-17 and Monocytes Expressing Markers of Alternative Activation in Patients with Sepsis [J].
Colo Brunialti, Milena Karina ;
Santos, Michelle Carolina ;
Rigato, Otelo ;
Machado, Flavia Ribeiro ;
Silva, Eliezer ;
Salomao, Reinaldo .
PLOS ONE, 2012, 7 (05)
[6]   KINETICS AND CORRELATION WITH BODY-TEMPERATURE OF CIRCULATING INTERLEUKIN-6, INTERLEUKIN-8, TUMOR-NECROSIS-FACTOR-ALPHA AND INTERLEUKIN-1-BETA IN PATIENTS WITH FEVER AND NEUTROPENIA [J].
ENGEL, A ;
KERN, WV ;
MURDTER, G ;
KERN, P .
INFECTION, 1994, 22 (03) :160-164
[7]   Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America [J].
Freifeld, Alison G. ;
Bow, Eric J. ;
Sepkowitz, Kent A. ;
Boeckh, Michael J. ;
Ito, James I. ;
Mullen, Craig A. ;
Raad, Issam I. ;
Rolston, Kenneth V. ;
Young, Jo-Anne H. ;
Wingard, John R. .
CLINICAL INFECTIOUS DISEASES, 2011, 52 (04) :E56-E93
[8]  
Goldstein Brahm, 2005, Pediatr Crit Care Med, V6, P2
[9]  
GORGEN I, 1992, J IMMUNOL, V149, P918
[10]   EFFECT OF GRANULOCYTE-COLONY-STIMULATING FACTOR TREATMENT ON EX-VIVO BLOOD CYTOKINE RESPONSE IN HUMAN VOLUNTEERS [J].
HARTUNG, T ;
DOCKE, WD ;
GANTNER, F ;
KRIEGER, G ;
SAUER, A ;
STEVENS, P ;
VOLK, HD ;
WENDEL, A .
BLOOD, 1995, 85 (09) :2482-2489